<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00441961</url>
  </required_header>
  <id_info>
    <org_study_id>mtx in eosinophilic fasciitis</org_study_id>
    <nct_id>NCT00441961</nct_id>
  </id_info>
  <brief_title>Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis</brief_title>
  <official_title>Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effect of high dose MTX on skin induration in patients with eosinophilic fascia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eosinophilic fasciitis (EF)is a fibrosing skin disorder extensively involving the deep&#xD;
      fascia. The aim of this pilot study is to evaluate the effect of high dose MTX on skin&#xD;
      induration in patients with EF. In addition, we study the effect of this treatment on joint&#xD;
      mobility, peripheral blood eosinophilia, functional ability, and pulmonary function. By&#xD;
      administering high dose MTX intravenously every four weeks with a Leukovorin rescue, we hope&#xD;
      to induce a more pronounced and sustained effect on the involved skin with less&#xD;
      (long-lasting) side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy is evaluated after 6 months.</measure>
    <time_frame>December 2008</time_frame>
  </primary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Fasciitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>methotrexate</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eosinophilic fasciitis as defined by clinical judgement of an expert,&#xD;
&#xD;
          -  Histologically confirmed with a skin-fascia-muscle biopsy, and in additon:&#xD;
&#xD;
               -  Either the presence of a modified skin score according to Zachariae of 8 or&#xD;
                  higher (0-18), regarded as a generalised eosinophilic fasciitis or the presence&#xD;
                  of severe contractures due to eosinophilic fasciitis lesions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 yrs&#xD;
&#xD;
          -  Contraindications to MTX: AST/ALT level &gt; 2 times upper limit of normal, WBC count &lt;&#xD;
             3.5 x 109/l or platelet count &lt; 150 x 109/l, serum creatinine &gt; 130 micromol/l or&#xD;
             clearance &lt; 50 ml/min, confirmed by two repeated tests within one month.&#xD;
&#xD;
          -  Chronic liver disease, insulin dependant diabetes mellitus, alcohol abuse&#xD;
&#xD;
          -  Restrictive pulmonary disease (total lung capacity or vital capacity &lt; 40% of&#xD;
             predicted) or interstitial lung disease (KCO &lt; 60% of predicted)&#xD;
&#xD;
          -  Pregnancy or child bearing potential without adequate contraception&#xD;
&#xD;
          -  The presence of any serious co-morbidity or malignancy&#xD;
&#xD;
          -  Use of other anti-folate drugs than MTX&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Knaapen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2007</study_first_posted>
  <last_update_submitted>August 10, 2011</last_update_submitted>
  <last_update_submitted_qc>August 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>H. Knaapen, MD</name_title>
    <organization>Radboud University</organization>
  </responsible_party>
  <keyword>Eosinophilic fasciitis, Shulman's syndrome, methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

